203 related articles for article (PubMed ID: 36004583)
1. Cationically modified inhalable nintedanib niosomes: enhancing therapeutic activity against non-small-cell lung cancer.
K Shukla S; Nguyen V; Goyal M; Gupta V
Nanomedicine (Lond); 2022 Jun; 17(13):935-958. PubMed ID: 36004583
[No Abstract] [Full Text] [Related]
2. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
3. Highly in vitro anti-cancer activity of melittin-loaded niosomes on non-small cell lung cancer cells.
Honari P; Shahbazzadeh D; Behdani M; Pooshang Bagheri K
Toxicon; 2024 Apr; 241():107673. PubMed ID: 38432612
[TBL] [Abstract][Full Text] [Related]
4. Delivery of vinblastine-containing niosomes results in potent in vitro/in vivo cytotoxicity on tumor cells.
Amiri B; Ahmadvand H; Farhadi A; Najmafshar A; Chiani M; Norouzian D
Drug Dev Ind Pharm; 2018 Aug; 44(8):1371-1376. PubMed ID: 29532687
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.
Kala SG; Chinni S
Drug Deliv Transl Res; 2022 Nov; 12(11):2856-2864. PubMed ID: 35322372
[TBL] [Abstract][Full Text] [Related]
6. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
[TBL] [Abstract][Full Text] [Related]
7. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity.
Qumbar M; Ameeduzzafar ; Imam SS; Ali J; Ahmad J; Ali A
Biomed Pharmacother; 2017 Sep; 93():255-266. PubMed ID: 28738502
[TBL] [Abstract][Full Text] [Related]
8. Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy.
Elbatanony RS; Parvathaneni V; Kulkarni NS; Shukla SK; Chauhan G; Kunda NK; Gupta V
Drug Deliv Transl Res; 2021 Jun; 11(3):927-943. PubMed ID: 32557351
[TBL] [Abstract][Full Text] [Related]
9. Formulation, optimization and evaluation of amisulpride-loaded niosomal intranasal gel for brain targeting.
Patil VS; Sutar KP; Pockle RD; Usulkar S; Jadhav VA
Ther Deliv; 2023 Oct; 14(10):635-647. PubMed ID: 38050965
[TBL] [Abstract][Full Text] [Related]
10. The Optimized Formulation of Tamoxifen-Loaded Niosomes Efficiently Induced Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.
Akbarzadeh I; Farid M; Javidfar M; Zabet N; Shokoohian B; Arki MK; Shpichka A; Noorbazargan H; Aghdaei HA; Hossein-Khannazer N; Timashev P; Makvandi P; Vosough M
AAPS PharmSciTech; 2022 Jan; 23(1):57. PubMed ID: 35048234
[TBL] [Abstract][Full Text] [Related]
11. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
12. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of optimized zolmitriptan niosomal emulgel.
Mohamed MI; Abdelbary AA; Kandil SM; Mahmoud TM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1157-1167. PubMed ID: 30919700
[No Abstract] [Full Text] [Related]
14. Development of novel diolein-niosomes for cutaneous delivery of tretinoin: influence of formulation and in vitro assessment.
Manca ML; Manconi M; Nacher A; Carbone C; Valenti D; Maccioni AM; Sinico C; Fadda AM
Int J Pharm; 2014 Dec; 477(1-2):176-86. PubMed ID: 25455770
[TBL] [Abstract][Full Text] [Related]
15. Non-ionic surfactant vesicles as a carrier system for dermal delivery of (+)-Catechin and their antioxidant effects.
Li D; Martini N; Liu M; Falconer JR; Locke M; Wu Z; Wen J
J Drug Target; 2021 Mar; 29(3):310-322. PubMed ID: 33044095
[TBL] [Abstract][Full Text] [Related]
16. Development and biological evaluation of Gymnema sylvestre extract-loaded nonionic surfactant-based niosomes.
Kamble B; Talreja S; Gupta A; Patil D; Pathak D; Moothedath I; Duraiswamy B
Nanomedicine (Lond); 2013 Aug; 8(8):1295-305. PubMed ID: 23259778
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.
Sawant SS; Patil SM; Shukla SK; Kulkarni NS; Gupta V; Kunda NK
Drug Deliv Transl Res; 2022 Oct; 12(10):2474-2487. PubMed ID: 34816394
[TBL] [Abstract][Full Text] [Related]
18. The effect of noisome preparation methods in encapsulating 5-fluorouracil and real time cell assay against HCT-116 colon cancer cell line.
Ugorji OL; Umeh ONC; Agubata CO; Adah D; Obitte NC; Chukwu A
Heliyon; 2022 Dec; 8(12):e12369. PubMed ID: 36582708
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation.
Mohsen AM; AbouSamra MM; ElShebiney SA
Drug Dev Ind Pharm; 2017 Aug; 43(8):1254-1264. PubMed ID: 28330377
[TBL] [Abstract][Full Text] [Related]
20. Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement.
Kamboj S; Saini V; Bala S
ScientificWorldJournal; 2014; 2014():959741. PubMed ID: 24672401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
